Obsidian Therapeutics Inc.
Obsidian Therapeutics Inc.
- Market cap
- $12.70M
- P/E ratio
- 0.08
Your view on OBX
Overview
What the company does, where it operates, and who runs it.
About Obsidian Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Not available
- Headquarters
- 1030 Massachusetts Avenue, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Not available
- Headquarters
- 1030 Massachusetts Avenue, Cambridge, MA, US
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors.
Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Obsidian Therapeutics Inc.. Starting points for Obsidian Therapeutics Inc.: P/E 0.1, EPS $1.39, beta 2.64 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Obsidian Therapeutics Inc.. Trailing twelve-month EPS for Obsidian Therapeutics Inc. stands at $1.39. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Targets, low to high
Earnings per share estimates
| Per share | This quarterMar 2025 | Next quarterJun 2025 | This yearYear to Dec 2024 | Next yearYear to Dec 2025 |
|---|---|---|---|---|
| Average estimate | −$58.89 | $165.45 | −$16.40 | −$156.13 |
| Lowest estimate | −$58.89 | $165.45 | −$16.40 | −$156.13 |
| Highest estimate | −$58.89 | $165.45 | −$16.40 | −$156.13 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Revenue estimates
| Total | This quarterMar 2025 | Next quarterJun 2025 | This yearYear to Dec 2024 | Next yearYear to Dec 2025 |
|---|---|---|---|---|
| Average estimate | $50.00M | $50.00M | $50.00M | $0.00 |
| Lowest estimate | $50.00M | $50.00M | $50.00M | $0.00 |
| Highest estimate | $50.00M | $50.00M | $50.00M | $0.00 |
| Number of analysts | 1 | 1 | — | 0 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Obsidian Therapeutics Inc.. Obsidian Therapeutics Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| AGMBAgomAb Therapeutics N.V. American Depositary Shares | Healthcare | NASDAQ | $313.2M | ||
| AGN.AXArgenica Therapeutics Ltd | Healthcare | ASX | — | ||
| AGNPFAlgernon Pharmaceuticals Inc. | Healthcare | OTC | $1.1M | ||
| AGTXAgentix Corp. | Healthcare | OTC | $1.9M | ||
| AIMAIM ImmunoTech Inc. | Healthcare | AMEX | $5.7M | ||
| AIMDAinos, Inc. | Healthcare | NASDAQ | $9.1M | ||
| AIMDWAinos, Inc. | Healthcare | NASDAQ | $2.7M | ||
| AKBAAkebia Therapeutics, Inc. | Healthcare | NASDAQ | $131.7M | ||
| AKBLFALK-Abelló A/S | Healthcare | OTC | $7.3B | ||
| AKTXAkari Therapeutics, Plc | Healthcare | NASDAQ | $15.6M | ||
| ALA.AXArovella Therapeutics Limited | Healthcare | ASX | — | ||
| ALDXAldeyra Therapeutics, Inc. | Healthcare | NASDAQ | $38.9M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.01% | |
| SCHASchwab U.S. Small-Cap ETF | $21.7B in assets | 0.01% | |
| GISCGuggenheim Funds Trust - Guggenheim Securitized Income ETF | $93M in assets | 0.09% | |
| ITOTiShares Core SP Total US Stock Market ETF | $93.2B in assets | 0.00% | |
| SCHBSchwab U.S. Broad Market ETF | $43.2B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in OBX.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Obsidian Therapeutics Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Obsidian Therapeutics Inc.. Coverage tracks Obsidian Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Obsidian Therapeutics Inc.